Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00111813 · OUTCOME

Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) · Source last updated 2015-05-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Days
Interval / dispersion
Standard Deviation
Time frame
Day 1 to disease progression, toxicity, or death, assessed up to 29 months

What was measured

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.

Groups in this outcome

Vorinostat 200 mg + Bortezomib 0.7 mg/m^2

Vorinostat capsules given twice daily (b.i.d.). Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 4, 8, 11, and 15 of each cycle).

Vorinostat 200 mg + Bortezomib 0.9 mg/m^2

Vorinostat capsules given b.i.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 4, 8, 11, and 15 of each cycle).

Vorinostat 300 mg + Bortezomib 1.3 mg/m^2

Vorinostat capsules given once daily (q.d.). Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 1, 4, 8, and 11 of each cycle).

Vorinostat 400 mg + Bortezomib 0.9 mg/m^2

Vorinostat capsules given q.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 1, 4, 8, and 11 of each cycle).

Vorinostat 400 mg + Bortezomib 1.1 mg/m^2

Vorinostat capsules given q.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 1, 4, 8, and 11 of each cycle).

Vorinostat 400 mg + Bortezomib 1.3 mg/m^2

Vorinostat capsules given q.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 1, 4, 8, and 11 of each cycle).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Vorinostat 200 mg + Bortezomib 0.7 mg/m^23
Vorinostat 200 mg + Bortezomib 0.9 mg/m^23
Vorinostat 300 mg + Bortezomib 1.3 mg/m^210
Vorinostat 400 mg + Bortezomib 0.9 mg/m^26
Vorinostat 400 mg + Bortezomib 1.1 mg/m^26
Vorinostat 400 mg + Bortezomib 1.3 mg/m^26

Reported measurements

Source class 1
Values in Days · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Vorinostat 200 mg + Bortezomib 0.7 mg/m^2NANANot reportedNot reportedNo participants had a dose modification at this dose.
Vorinostat 200 mg + Bortezomib 0.9 mg/m^2NANANot reportedNot reportedNo participants had a dose modification at this dose.
Vorinostat 300 mg + Bortezomib 1.3 mg/m^25839Not reportedNot reportedNot reported
Vorinostat 400 mg + Bortezomib 0.9 mg/m^25811Not reportedNot reportedNot reported
Vorinostat 400 mg + Bortezomib 1.1 mg/m^2128148Not reportedNot reportedNot reported
Vorinostat 400 mg + Bortezomib 1.3 mg/m^2325Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        No participants had a dose modification at this dose.
        group Id
        OG000
        spread
        NA
        value
        NA
      2. comment
        No participants had a dose modification at this dose.
        group Id
        OG001
        spread
        NA
        value
        NA
      3. group Id
        OG002
        spread
        39
        value
        58
      4. group Id
        OG003
        spread
        11
        value
        58
      5. group Id
        OG004
        spread
        148
        value
        128
      6. group Id
        OG005
        spread
        5
        value
        32
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      10
    4. group Id
      OG003
      value
      6
    5. group Id
      OG004
      value
      6
    6. group Id
      OG005
      value
      6
    units
    Participants
description
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience.
dispersion Type
Standard Deviation
groups
  1. description
    Vorinostat capsules given twice daily (b.i.d.). Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 4, 8, 11, and 15 of each cycle).
    id
    OG000
    title
    Vorinostat 200 mg + Bortezomib 0.7 mg/m^2
  2. description
    Vorinostat capsules given b.i.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 4, 8, 11, and 15 of each cycle).
    id
    OG001
    title
    Vorinostat 200 mg + Bortezomib 0.9 mg/m^2
  3. description
    Vorinostat capsules given once daily (q.d.). Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 1, 4, 8, and 11 of each cycle).
    id
    OG002
    title
    Vorinostat 300 mg + Bortezomib 1.3 mg/m^2
  4. description
    Vorinostat capsules given q.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 1, 4, 8, and 11 of each cycle).
    id
    OG003
    title
    Vorinostat 400 mg + Bortezomib 0.9 mg/m^2
  5. description
    Vorinostat capsules given q.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 1, 4, 8, and 11 of each cycle).
    id
    OG004
    title
    Vorinostat 400 mg + Bortezomib 1.1 mg/m^2
  6. description
    Vorinostat capsules given q.d. Treatment in 21 day cycles (participants received vorinostat for 14 days followed by a 7 day break). Bortezomib injection. Treatment in 21 day cycles (participants received bortezomib on Days 1, 4, 8, and 11 of each cycle).
    id
    OG005
    title
    Vorinostat 400 mg + Bortezomib 1.3 mg/m^2
param Type
MEAN
reporting Status
POSTED
time Frame
Day 1 to disease progression, toxicity, or death, assessed up to 29 months
title
Mean Time to First AE Resulting in a Dose Modification in Either Vorinostat or Bortezomib
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice